<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604211</url>
  </required_header>
  <id_info>
    <org_study_id>KGraubuenden</org_study_id>
    <nct_id>NCT03604211</nct_id>
  </id_info>
  <brief_title>SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience</brief_title>
  <official_title>Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Graubuenden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kantonsspital Graubuenden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-institution retrospective analysis for predictive factors of prostate cancer patients
      presenting with isolated or limited lymph node (LN) recurrence (1-3 lesions) on F-Ccholine
      PET-CT (CholPET) treated with SBRT between January 2010 and July 2015.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-institution retrospective analysis of consecutive prostate cancer patients after
      definitive primary treatment, without local recurrence, presenting with isolated or limited
      lymph node (LN) recurrence (1-3 lesions) on F-Ccholine PET-CT (CholPET) treated with SBRT
      between January 2010 and July 2015.

      Endpoints of interest are biochemical response rate (defined as a reduction by at least 10%
      of the initial PSA value), time to biochemical recurrence (TBR) (defined as the time interval
      from SBRT until second PSA rise), and time interval between SBRT and ADT start. Univariate
      analysis is used to identify prognostic factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>time to biochemical recurrence</measure>
    <time_frame>18 months</time_frame>
    <description>time interval from SBRT until second PSA rise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical response rate</measure>
    <time_frame>18 months</time_frame>
    <description>reduction by at least 10% of the initial PSA value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time interval between SBRT and ADT start</measure>
    <time_frame>18 months</time_frame>
    <description>time interval between SBRT and ADT start</description>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <condition>Prostate Cancer</condition>
  <condition>Lymph Node Metastases</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cyberknife Radiation Therapy</intervention_name>
    <description>Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        single-Institution cohort of male patients 18-85 years of age, with recurrent prostate
        cancer after radical prostatectomy in 1-3 lymphnodes, prospectively registered in a local
        institutional database
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven diagnosis of prostate cancer

          -  Radical prostatectomy (± salvage radiotherapy)

          -  PSA relapse (defined by two consecutive rising PSA values &gt;0.2 ug/l)

          -  one to three lymphnodes positive on Choline-PET

          -  no recurrence in prostatic bed on Choline-PET

          -  WHO performance status of 0-1

          -  no previous chemotherapy or ADT for prostate cancer.

        Exclusion Criteria:

          -  primary treatment for prostate cancer by RT or brachytherapy

          -  bone (M1b) metastases

          -  visceral (M1c) metastases

          -  any symptomatic nodal lesion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniel R Zwahlen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kantonsspital Graubuenden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juergen Curschmann</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

